Prot #R2176-3-AMD-1417: A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-Ralated Macular Degeneration

Project: Research project

Project Details

StatusFinished
Effective start/end date5/19/155/19/18

Funding

  • Parexel (Prot #R2176-3-AMD-1417)
  • Regeneron Pharmaceuticals, Inc. (Prot #R2176-3-AMD-1417)